AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24337761
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg/day for 15 days
Trial: 21855271
Drug: Proximal surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal surface treatment with hydroxyapatite coating
Trial: 21855271
Drug: Proximal surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal surface treatment without hydroxyapatite coating
Trial: 11235062
Drug: Natural progesterone
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural progesterone creams
Trial: 9683116
Drug: Geragogy-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geragogy-based medication instruction
Trial: 9683116
Drug: Usual preprinted
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual preprinted discharge instructions with handwritten medication information
Trial: 27760062
Drug: Brief Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Intervention (BI) and Cognitive Behavioral Therapy (CBT)
Trial: 22489518
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation treatment assisted with orthopedic footwear
Trial: 22489518
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation treatment only (Control)
Trial: 7926297
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to 37k antigen
Trial: 7926297
Drug: Antibodies to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies to GAD
Trial: 7926297
Drug: GAD antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD antibody levels
Trial: 2574190
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nizatidine every 8 hours
Trial: 2574190
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg nizatidine every 12 hours
Trial: 31242931
Drug: Transdermal GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal GTN (5 mg/day), administered as a transdermal patch by paramedics in the prehospital setting within 3 h of stroke onset and continued for 24 h
Trial: 26522892
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 10mg (0.4mL) of bevacizumab
Trial: 26522892
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with verteporfin (6mg/m²)
Trial: 26522892
Drug: Combined treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment: subconjunctival injection of bevacizumab followed by photodynamic therapy 7 days later
Trial: 11284817
Drug: esmolol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esmolol 1.5 mg.kg‐1
Trial: 6356756
Drug: Midazolam (0.13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.13 mg/kg)
Trial: 19319008
Drug: Office-based vergence/accommodative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based vergence/accommodative therapy
Trial: 29352425
Drug: Nanocurcumin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin (80 mg daily)
Trial: 27496096
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy plus medical treatment with slow release bupropion)
Trial: 27496096
Drug: Brief advice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief advice (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy)
Trial: 27496096
Drug: Control (just
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (just TB medical treatment)
Trial: 21885174
Drug: Paricalcitol, 1
RxNorm normalized name: Paricalcitol, 1 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol, 1 or 2 μg/d for 16 weeks
Trial: 21885174
Drug: Ergocalciferol, 50,000
RxNorm normalized name: Ergocalciferol, 50,000 intl units oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol, 50,000 units titrated to achieve serum levels ≥30 ng/mL for 16 weeks
Trial: 14711888
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL glucose 30%
Trial: 14711888
Drug: 0.4 mL
RxNorm normalized name: ethanol 0.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mL glucose 30%
Trial: 14711888
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL water (control)
Trial: 11376913
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion into the masseter muscle
Trial: 11376913
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion into the anterior tibialis muscle
Trial: 9246149
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg BID
Trial: 9246149
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg TID
Trial: 8432921
Drug: Intradermal injections
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injections of allergen-antibody complexes
Trial: 3109461
Drug: Intravenous mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mesna (800 mg)
Trial: 3109461
Drug: Oral mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mesna (800 mg)
Trial: 29800034
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n=77)
Trial: 24166586
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Adefovir plus 100 mg Lamivudine (combination therapy)
Trial: 24166586
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Adefovir (monotherapy)
Trial: 20661939
Drug: 10‐g Semmes‐Weinstein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐g Semmes‐Weinstein monofilament and 128‐Hz tuning fork examinations
Trial: 16617567
Drug: Dose-intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intensified chemotherapy
Trial: 9570681
Drug: Standard-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose therapy
Trial: 3717101
Drug: Sustained-release terbutaline
RxNorm normalized name: terbutaline Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release terbutaline sulfate, 5 mg twice daily
Trial: 3717101
Drug: Sustained-release terbutaline
RxNorm normalized name: terbutaline Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release terbutaline sulfate, 7.5 mg twice daily
Trial: 3717101
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (doses adjusted to achieve serum concentrations of 10 to 20 mg/L)
Trial: 23273853
Drug: Neurodevelopmental therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental therapy-based exercise therapy (Control group).
Trial: 20814967
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg
Trial: 20814967
Drug: Subcutaneous teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous teriparatide 20 µg
Trial: 18281442
Drug: Deferasirox (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (20 mg/kg) administered before a high-fat or standard breakfast
Trial: 18281442
Drug: Deferasirox (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (20 mg/kg) administered concurrently with a standard breakfast
Trial: 18281442
Drug: Deferasirox (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (20 mg/kg) administered under fasted conditions
Trial: 18281442
Drug: Deferasirox (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (20 mg/kg) administered at least 30 minutes before a meal
Trial: 18281442
Drug: Deferasirox (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (20 mg/kg) administered consistently at the same time before meals
Trial: 16476694
Drug: AZD6140 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6140 100 mg bid
Trial: 16476694
Drug: AZD6140 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6140 200 mg bid
Trial: 16476694
Drug: AZD6140 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6140 50 mg bid
Trial: 14601905
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by surgery
Trial: 30572339
Drug: 500-mg Salvia
RxNorm normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mg Salvia officinalis capsules once a day for 2 consecutive months
Trial: 29357859
Drug: IDN 5933
RxNorm normalized name: IDN-7314
DrugBank: IDN-7314 (DB18073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDN 5933 (Ginkgoselect®Plus) 120 mg twice daily for 6 months
Trial: 27089068
Drug: Sequential monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential monotherapy (strategy 1)
Trial: 27089068
Drug: Step-up combination
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up combination therapy (strategy 2)
Trial: 27089068
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with prednisone (strategy 3)
Trial: 27089068
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with infliximab (strategy 4)
Trial: 24891067
Drug: Prucalopride 4
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prucalopride 4 mg per day for 6 days
Trial: 22340631
Drug: Cetuximab (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (250 mg/m2 I.V. on days 1, 8, and 15) + Mitoxantrone (12 mg/m2 I.V. on day 1) + Prednisone (10 mg daily)
Trial: 22340631
Drug: Mitoxantrone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (12 mg/m2 I.V. on day 1) + Prednisone (10 mg daily)
Trial: 16026370
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion pump (CSII)
Trial: 12447952
Drug: Cefepime or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime or carbapenem monotherapy
Trial: 12447952
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cefepime and aminoglycoside
Trial: 8523940
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms of inhaled terbutaline for two consecutive days
Trial: 8523940
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms of inhaled terbutaline
Trial: 1936483
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + SU
Trial: 1936483
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + SU
Trial: 7013087
Drug: Amitriptyline alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline alone or in combination with fluphenazine hydrochloride
Trial: 31544375
Drug: Ultrasound-guided acupoint
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided acupoint electrical stimulation therapy (30 min, 3 times a day for 7 days)
Trial: 24156189
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy with Emotional‐Approach Coping (MT/EAC)
Trial: 22368863
Drug: Ginsenoside Rb1
RxNorm normalized name: Ginsenoside Rb1
DrugBank: Ginsenoside Rb1 (DB06749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside Rb1 (10 mg x kg(‐1) administered intraperitoneally once a day)
Trial: 22368863
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline 10 mL x kg(‐1) administered intraperitoneally once a day)
Trial: 22368863
Drug: Model group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model group (saline 10 mL x kg(‐1) administered intraperitoneally once a day)
Trial: 19702487
Drug: d‐MPH XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH XR 10 mg o.d.
Trial: 19702487
Drug: d‐MPH XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH XR 20 mg o.d.
Trial: 19702487
Drug: d‐MPH XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐MPH XR 30 mg o.d.
Trial: 30700274
Drug: Quadrivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent vaccine
Trial: 15510233
Drug: Budenofalk 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budenofalk 9 mg once daily (o.d.)
Trial: 15510233
Drug: Budenofalk 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budenofalk 3 mg three times a day (t.i.d.)
Trial: 1618070
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg)
Trial: 3126348
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) 0.75 mg/kg over 90 min
Trial: 3126348
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase 1,500,000 IU over 60 min
Trial: 29180023
Drug: Patiromer (8.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer (8.4 g/d or 16.8 g/d for 4 weeks)
Trial: 21982351
Drug: Formulations with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations with 1.0% and 5.0% panthenol
Trial: 21982351
Drug: Formulations with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations with panthenol after skin washing with sodium laureth sulphate (SLES)
Trial: 12873431
Drug: L-[1-13C] phenylalanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-[1-13C] phenylalanine breath test (PBT)
Trial: 1855327
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (SS)
Trial: 6681030
Drug: Three-monthly assessments
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-monthly assessments
Trial: 24571702
Drug: Stabilised stannous
RxNorm normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilised stannous (Sn)-containing NaF dentifrice (Oral B/blend-a-Med Pro-Expert)
Trial: 22101220
Drug: Early childhood
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early childhood obesity intervention (no specific dosage or duration mentioned)
Trial: 16192762
Drug: Ropivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine with epinephrine (5 mug/ml)
Trial: 14515631
Drug: Non-submerged loaded
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-submerged loaded (NSL) implants
Trial: 14515631
Drug: Non-submerged non-loaded
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-submerged non-loaded (NSNL) implants
Trial: 14515631
Drug: Submerged (S)
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submerged (S) implants
Trial: 3890461
Drug: Topical 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1.0% indomethacin (5-drop loading dose, applied pre-operatively and post-operatively every 3 hours)
Trial: 29931588
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) combined with functional exercise program (n=11)
Trial: 23279452
Drug: Lumbar interlaminar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumbar interlaminar injections containing a local anesthetic (lidocaine 0.5%, 6 mL)
Trial: 23279452
Drug: Lumbar interlaminar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumbar interlaminar epidural injections of 0.5% lidocaine, 5 mL, mixed with 1 mL of non‐particulate betamethasone
Trial: 20167441
Drug: Standard antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiviral HCV therapy with pegylated interferon and ribavirin
Trial: 24169031
Drug: Beauty treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beauty treatments during hospitalization
Trial: 24169031
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no beauty treatments)
Trial: 1378137
Drug: Carvedilol (12.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (12.5-50 mg b.i.d. for 4-8 weeks)
Trial: 3000138
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ACTH 4-9 analogue (Org 2766)
Trial: 18670743
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (lentinan, RFA, and TACE)
Trial: 31848169
Drug: Belimumab administered
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab administered 4 to 8 weeks after the first rituximab infusion for 52 weeks
Trial: 31848169
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 4 to 8 weeks after the first rituximab infusion for 52 weeks
Trial: 26040429
Drug: Pramlintide 6
RxNorm normalized name: PRAMLINTIDE 600MCG/ML SOLN INJ 5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide 6 mcg/unit insulin
Trial: 26040429
Drug: Pramlintide 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide 9 mcg/unit insulin
Trial: 26040429
Drug: Pramlintide 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide 12 mcg/unit insulin
Trial: 24375222
Drug: 16 mL
RxNorm normalized name: 16 ML Mvasi 25 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mL of 0.1285% ropivacaine
Trial: 15080229
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Therapy (FET)
Trial: 17341866
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied indigo naturalis ointment
Trial: 12505248
Drug: Active hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri)
Trial: 12505248
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for hormone replacement therapy
Trial: 9869222
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (surgery and radiotherapy)
Trial: 773493
Drug: Bran tablets
RxNorm normalized name: bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bran tablets
Trial: 17439510
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily for 1 week, followed by 3 weeks of esomeprazole 40 mg daily
Trial: 11288947
Drug: Thromboprophylactic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboprophylactic agents (specific agents not mentioned)